Crisugabalin
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Crisugabalin (HSK16149) is a novel GABA analog in development for the treatment of chronic pain. It has a wider therapeutic index than pregabalin, which has a similar mechanism of action. In China, it was approved in May 2024 for the treatment of diabetic peripheral neuropathy with neuropathic pain and approved in July 2024 for the treatment of postherpetic neuralgia.
In the United States, it is in Phase III trials as of 2023. The drug can be administered with or without food.
Crisugabalin (HSK16149) is a novel GABA analog in development for the treatment of chronic pain. It has a wider therapeutic index than pregabalin, which has a similar mechanism of action. In China, it was approved in May 2024 for the treatment of diabetic peripheral neuropathy with neuropathic pain and approved in July 2024 for the treatment of postherpetic neuralgia.
In the United States, it is in Phase III trials as of 2023. The drug can be administered with or without food.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1377083067 under CC BY-SA 4.0; modifications have been made.